Qvanteq AG develops novel biofunctional surfaces to address and overcome the clinical adverse effects of today’s vascular stents.
Qvanteq’s Qstent technology stands for reduced thrombus formation and fast healing.
Qvanteq AG was founded in early 2009 and is held by private investors. Qvanteq is ISO 13485 certified. The company is based at the Technopark in Zurich, Switzerland. Qvanteq is a spin-off company from the Swiss Federal Institute of Technology (ETH) Zurich. The company was awarded with the CTI start-up label in 2012.